Durable response of immune checkpoint inhibitor after failure of gemcitabine-based chemotherapy for a patient with metastatic biliary tract cancer

Journal of Cancer Research and Practice Pub Date : 2021-01-01 DOI:10.4103/jcrp.jcrp_22_21

Chiun Hsu, Chien-Huai Chuang

引用次数: 0

查看原文本刊更多论文

转移性胆道癌患者吉西他滨化疗失败后免疫检查点抑制剂的持久反应

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer Research and Practice

自引率

0.00%

发文量

审稿时长

24 weeks

期刊介绍： JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.